MRNA · News · 20260804N

Product / Drug Pipeline Progress

Moderna, Inc. · 2026-08-04 · Importance 31 · Surprise 42 · In source text

Moderna initiated a Phase 1 clinical trial in Canada for mRNA-1469, an investigational vaccine against Bundibugyo ebolavirus disease. The study is expected to enroll approximately 80 healthy adults and will evaluate safety, tolerability, and immune response. The target strain has caused an Ebola outbreak in the Democratic Republic of the Congo and currently has no licensed vaccine. The program is part of an expanded collaboration with the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million and is supporting plans for rapid availability of at least 500,000 doses for low- and middle-income countries if the vaccine is licensed.

Key facts

• The program is part of an expanded collaboration with CEPI, which has committed up to US$50 million to support its development. source
• CEPI is backing the program with up to $50 million, aiming to accelerate vaccine development. source
• CEPI pledged $50 million of support for the trial. source
• CEPI intends to ensure rapid availability of at least 500,000 doses for low- and middle-income countries if licensed. source
• Health Canada has approved Moderna to begin a Phase I clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. source
• The trial, aiming to enroll approximately 80 healthy adults, will assess the vaccine's safety and immune response. source
• The trial will enroll approximately 80 healthy adults in Canada to assess safety, tolerability, and immune response. source
• Following Health Canada's authorization, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company's investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus, or BDBV, disease. source

Impact estimates